For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Colestyramine - Lipid modification
PAD Profile : Colestyramine - Lipid modification
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Atorvastatin
- Rosuvastatin calcium
- Simvastatin
- Ezetimibe
- Pravastatin sodium
- Fluvastatin sodium
- Evolocumab
- Alirocumab
- Fenofibrate
- Bezafibrate
- Ciprofibrate
- Gemfibrozil
- Colesevelam hydrochloride
- Bempedoic acid
- Inclisiran
- Icosapent
Other Indications
Additional Documents
Committee Recommendations
The PCN recommends, as per NICE CG71 (updated July 2016), that patients with Familial Hyperchosterolaemia (FH) with intolerance or contraindications to statins or ezetimibe, should be offered a referral to a specialist with expertise in FH for consideration for treatment with either a bile acid sequestrant (resin), nicotinic acid or a fibrate to reduce their LDL-C concentration. For those patients, bile acid sequestrants should be considered BLUE (without an information sheet) on the traffic light system Specialists to initiate treatment or make a recommendation for the primary care prescriber to initiate treatment.
See below for policy statement and further information